Affiner les résultats
Type de document
Institution
Collection spécifique
Langue
- Anglais (2)
Auteur
- Catapano, Carlo V. (2)
- Garcia-Escudero, Ramon (2)
- Albino, Domenico (1)
- Alimonti, Andrea (1)
- Bonanno, Elena (1)
- Bonfiglio, Rita (1)
- Carbone, Giuseppina M. (1)
- Chiorino, Giovanna (1)
- Civenni, Gianluca (1)
- Di Mitri, Diletta (1)
- Grassi, Fabio (1)
- Guccini, Ilaria (1)
- Jarrossay, David (1)
- Kalathur, Madhuri (1)
- Mapelli, Sarah N. (1)
- Marini, Camilla (1)
- Mello-Grand, Maurizia (1)
- Montani, Erica (1)
- Pandolfi, Pier Paolo (1)
- Pinton, Sandra (1)
- Proietti, Michele (1)
- Revandkar, Ajinkya (1)
- Sarti, Manuela (1)
- Scanziani, Eugenio (1)
- Scimeca, Manuel (1)
- Shinde, Dheeraj (1)
- Toso, Alberto (1)
- Zhang, Jiangwen (1) Plus Moins
Mot clé
- Gene classifier (1)
- Gene signature (1)
- Predictive biomarkers (1)
- Prosenescence therapy has recently emerged as a novel therapeutic approach for treating cancer. However (1)
- Prostate cancer (1)
- Tumor classification (1)
- activation of the Jak2/Stat3 pathway establishes an immunosuppressive tumor microenvironment that contributes to tumor growth and chemoresistance. Activation of the Jak2/Stat3 pathway in Pten-null tumors is sustained by the downregulation of the protein tyrosine phosphatase PTPN11/SHP2 (1)
- in Pten-null senescent tumors (1)
- providing evidence for the existence of a novel PTEN/SHP2 axis. Importantly (1)
- these data demonstrate that immune surveillance of senescent tumor cells can be suppressed in specific genetic backgrounds but also evoked by pharmacological treatments. (1)
- this concept is challenged by conflicting evidence showing that the senescence-associated secretory phenotype (SASP) of senescent tumor cells can have pro- as well as antitumorigenic effects. Herein (1)
- treatment with docetaxel in combination with a JAK2 inhibitor reprograms the SASP and improves the efficacy of docetaxel-induced senescence by triggering a strong antitumor immune response in Pten-null tumors. Altogether (1)
- we report that (1) Plus Moins